A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS
Phase 1
- Conditions
- Relapsed/Refractory AML or Higher-Risk MDSMedDRA version: 20.0Level: LLTClassification code: 10001941Term: AML Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10068361Term: MDS Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10066572Term: AML progression Class: 10029104Therapeutic area: Diseases [C] - Hemic and Lymphatic Diseases [C15]Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2023-510479-72-00
- Lead Sponsor
- Remix Therapeutics Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method